Scinai Immunotherapeutics Says It Received Nasdaq Notice Confirming Regained Compliance With Minimum Bid Price Rule
Share
Why It Matters
Scinai fixed a problem with Nasdaq rules about its stock price. Now the company is back in good standing with the exchange.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.